|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Partner program revenue | |||||
| Collaboration revenue | |||||
| Total revenues | |||||
| Operating expenses | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Depreciation and amortization | |||||
| Goodwill impairment | |||||
| Gain on settlement of contingent consideration | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Other income (expense) | |||||
| Interest expense | |||||
| Other income, net | |||||
| Total other income, net | |||||
| Loss before income taxes | |||||
| Income tax expense | |||||
| Net loss | |||||
| Net loss available to common stockholder basic | |||||
| Foreign currency translation adjustments | |||||
| Unrealized gain on marketable securities | |||||
| Comprehensive loss | |||||
| Net loss per share: basic (in usd per share) | |||||
| Net loss per share: diluted (in usd per share) | |||||
| Weighted-average common shares outstanding: basic (in shares) | |||||
| Weighted-average common shares outstanding: diluted (in shares) | |||||
Loading...